| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:2003-2009.)
© 2004 American Heart Association, Inc.
Hypertension |
Level and Hinders the Progression of Cardiac Injury in Hypertensive Rats
From the Fédération de Cardiologie, Hôpital Henri Mondor (M.B., J.-L.D.-R., L.H.); INSERM Unité 581, Hôpital Henri Mondor (C.A., G.C., M.C., M.-C.B., S.A., F.P.); INSERM Unité 400, Faculté de Médecine (T.B., J.B.S., J.-L.D.-R., L.H.); and Service de Santé Publique, Hôpital Henri Mondor (F.R.-T.), Créteil, France.
Correspondence to Françoise Pecker, INSERM Unité 581, Hôpital Henri Mondor, 94010 Créteil, France. E-mail francoise.pecker{at}im3.inserm.fr
Received May 10, 2004; revision received July 13, 2004; accepted July 15, 2004.
Background Studies in isolated cardiomyocytes showed that replenishment in cellular glutathione, achieved with the glutathione precursor N-acetylcysteine (NAC), abrogated deleterious effects of tumor necrosis factor-
(TNF-
).
Methods and Results We examined the ability of NAC to limit the progression of cardiac injury in the rat model of hypertension, induced by the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) (50 mg/kg per day SC) and high-salt diet (HS) (8% NaCl). Four-week HS/L-NAME administration induced hypertension (193±8 versus 122±4 mm Hg for low-salt diet [LS] group) and left ventricular (LV) dysfunction, revealed by echocardiography and characterized by decreased LV shortening fraction (38±2% versus 49±4% for LS group; P<0.05) and decreased LV posterior wall thickening (49±3% versus 70±4% for LS group; P<0.05). LV dysfunction worsened further after 6-week HS/LNAME administration. Importantly, increase in serum TNF-
level was strongly correlated with shortening fraction decrease and cardiac glutathione depletion. NAC (75 mg/d) was given as a therapeutic treatment in a subgroup of HS/L-NAME animals during weeks 5 and 6 of HS/L-NAME administration. NAC treatment, which replenished cardiac glutathione, had no effect on hypertension but reduced LV remodeling and dysfunction, normalized serum TNF-
level, and limited activation of matrix metalloproteinases -2 and -9 and collagen deposition in LV tissues.
Conclusions These findings suggest that glutathione status determines the adverse effects of TNF-
in cardiac failure and that TNF-
antagonism may be achieved by glutathione supplementation.
Key Words: tumor necrosis factor acetylcysteine glutathione heart failure NG-nitroarginine methyl ester
This article has been cited by other articles:
![]() |
N. Defer, A. Azroyan, F. Pecker, and C. Pavoine TNFR1 and TNFR2 Signaling Interplay in Cardiac Myocytes J. Biol. Chem., December 7, 2007; 282(49): 35564 - 35573. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Canton, A. Skyschally, R. Menabo, K. Boengler, P. Gres, R. Schulz, M. Haude, R. Erbel, F. Di Lisa, and G. Heusch Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization Eur. Heart J., April 1, 2006; 27(7): 875 - 881. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |